drugset / Trial / NCT06204679

Pharmacokinetics of Fixed-Dose Combination Tablet of Bemnifosbuvir and Ruzasvir

NCT06204679

Phase 1 Completed 42 enrolled Atea Pharmaceuticals, Inc.
RandomizedCrossoverOpen-labelTreatment

Summary

This study will assess comparative bioavailability and effect of food on a prototype fixed-dose combination (FDC) of Bemnifosbuvir (BEM) and Ruzasvir (RZR) in healthy subjects

Timeline

Start
2023-12-14
Primary completion
2024-08-25
Completion
2024-08-25

Drugs

EvaluationDrugModalityDoseRoute
Subject Bemnifosbuvir Other / unclassified
Subject Ruzasvir Other / unclassified

Indications

No indication recorded.